Repurposing anti-retroviral drugs to treat NF2-related tumours: a protocol for a phase 0 trial (RETREAT) Authors: Sarah Campbell, Katherine Beaney, Joanne Hosking, Lexy Sorrell, Victoria Allgar, Paigan J Aspinall, Sylwia Ammoun, D Gareth Evans, C O Hanemann, Sarah Kingdon Published: 2026 ABSTRACT AbstractIntroductionTo date, there is no proven licensed systemic treatment for neurofibromatosis type 2 (NF2)-related schwannomatosis patients. There is a need for more effective, less toxic treatments and, as a rare disease, NF2 is often overlooked in targeted drug development. Subcutaneous schwannomas of the skin (CS) are common in the NF2 population.This trial involves the repurposing of medications already licensed for HIV—ritonavir and lopinavir (Kaletra and Norvir)—that have been shown to reduce tumour growth by reducing cell proliferation in human schwannoma and meningioma tumour cell cultures. The safety and tolerability of these drugs are already known, so they are safe candidates to trial in NF2 patients.Methods and analysisThis trial is an open-label, phase 0 design. A maximum of 16 participants diagnosed with NF2-related schwannomatosis will be enrolled in this study. Treatment duration is 30 days, with a 30-day follow-up. Biopsies and blood samples will be collected to assess whether the drugs reach the tumours and to analyse the tumour-cell response. The primary outcome is pharmacodynamic response, defined as a statistically significant decrease in biomarker activity in CS biopsy samples at day 30. The sample size calculation is based on the tissue biomarker response.Ethics and disseminationThe study was approved by an Ethics Committee (West of Scotland Research Ethics Service (23/WS/0178)), the Health Research Authority (HRA), the Medicines and Healthcare products Regulatory Authority (MHRA) and each of the participating NHS Trust’s Research and Development departments. Following analysis of trial data, the trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences.Trial registration numberISRCTN10422213. STRENGTHS AND LIMITATIONS OF THIS STUDY Use of phase 0 design enabling rapid evaluation of potential treatments. Use of phase 0 design enabling rapid evaluation of potential treatments. Repurposing of drugs, which are usually well tolerated. Repurposing of drugs, which are usually well tolerated. Targets human endogenous retrovirus type K, which may have relevance for other cancers. Targets human endogenous retrovirus type K, which may have relevance for other cancers. Patients are their own controls, which makes pharmacodynamic readout more reliable. Patients are their own controls, which makes pharmacodynamic readout more reliable. Transferability of complex laboratory processes. Transferability of complex laboratory processes. Introduction Background and rationale Neurofibromatosis type 2 (NF2) is an autosomal dominant tumour pre-disposition syndrome characterised by the growth of bilateral vestibular schwannoma (VS), meningioma and ependymoma. NF2 typically presents in early adulthood with bilateral VS between 18 and 24 years1 2. It is associated with significant morbidity, with 50% of patients becoming wheelchair-dependent and an overall survival rate of 38% 20 years after diagnosis3 4. NF2 has a prevalence of 1 in 61 300 in the UK, with 73% de novo cases.5 Affected individuals may also develop schwannomas of peripheral or other central nerves.3 Cutaneous and/or subcutaneous schwannomas are present in up to 70% of NF2 patients on careful clinical examination.6 Current treatments and limitations The primary management of NF2-related tumours is surgery. Due to the additional risk of secondary malignancy, radiotherapy is reserved for inoperable cases where localised disease control is clinically necessary.7 NF2-related tumours are often slow-growing and unlikely to respond to cytotoxic chemotherapy; therefore, targeted agents offer an important therapeutic strategy.8 Bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor (VEGF) and is the only agent frequently used for the treatment of NF2-related VS, although it is not licensed. However, the clinical benefits are limited to those tumours that are moderately fast growing and there is no second-line option.9 Bevacizumab may have some benefit in meningioma but is also not licensed for this indication.10 The multi-tyrosine kinase inhibitor, brigatinib, has demonstrated activity in meningioma with a response rate of 10% in the target tumour and 23% in all tumours.11 Brigatinib has been shown to slow the growth rate of meningioma and non-VS, with a clinical improvement in hearing and pain reduction demonstrated. Several other medications have been investigated for NF2 patients; however, none have been shown to be effective at non-toxic doses.12 To date, there are no US Food and Drug Administration (FDA) or National Institute for Health and Care Excellence (NICE)-approved systemic treatment options for meningioma.8 There remains an urgent need for more effective and less toxic systemic therapies, particularly for patients with multiple or unresectable tumours.4 Target rationale in NF-2-related tumours The tumour suppressor protein Merlin, encoded by the NF2 gene, plays a crucial role in the development of NF2-related tumours. Loss of Merlin function is the driver in all sporadic schwannomas, 50–60% of meningiomas and a subgroup of ependymomas.1 12 13 Merlin loss has been implicated in other sporadic malignancies, including mesothelioma and glioblastoma.14 15 Recently, we showed a strong overexpression of human endogenous retrovirus type K (HERV-K) proteins (Env, Gag, Rec and NP9) in Merlin-negative schwannomas and meningiomas. HERV-K Env promotes proliferation and survival of schwannoma and meningioma cells in vitro involving JNK/c-Jun and RAS/RAF/MEK/Extracellular signal-regulated kinase (ERK) signalling pathways in schwannomas.16 This demonstrates the central role of Merlin loss in NF2-related tumour development and the rationale for exploring ways to target HERV-K. Rationale of HIV protease inhibitors: ritonavir and lopinavir Ritonavir and lopinavir are orally available retroviral protease inhibitors and are approved to treat HIV by preventing the cleavage of the Gag-Pol polyprotein. In addition to their role in HIV, ritonavir has an anti-cancer effect in HIV-related solid tumours, such as Kaposi’s sarcoma and non-Hodgkin's lymphoma.17 Recent translational studies have also found that they decrease the expression of retroviral proteins (Env and mature Gag) and reduce cellular proliferation in schwannomas and meningiomas.16 When comparing their specific effects, ritonavir was found to be more effective than lopinavir at reducing proliferation (as measured by Ki67 staining), particularly in meningioma cells.16 Lopinavir more effectively inhibited key proliferation pathways (pERK, cyclin D1) and reduced retroviral envelope (Env) protein. Lopinavir demonstrated equivalent efficacy in both meningioma and schwannoma cells, whereas ritonavir showed greater effectiveness in meningioma cells. Ritonavir potentiates lopinavir by inhibiting its metabolism and increasing its plasma concentrations. These complementary anti-proliferative mechanisms provide a strong rationale to combine both medications in the current clinical trial. Marketing authorisations (MAs) have been given for Norvir (tablets containing 100 mg ritonavir) and Kaletra (tablets consisting of 100 mg lopinavir and 25 mg ritonavir) in the UK for the treatment of HIV-1, and in this trial these two drugs will be used outside of their MA. Cutaneous schwannoma Previous early-phase clinical trials have included a biopsy of the central VS to investigate drug concentration and activity in the tissue, but a biopsy in this location can be challenging and carries a significant risk of morbidity, so it is not amenable or ethical to perform repeat sampling.18 This protocol uses a cutaneous (peripheral) schwannoma as a surrogate. It has molecular similarity to a central lesion but is safer to biopsy as it is more accessible; therefore, a repeat biopsy can be taken. and the CS is effectively its own control.19 20 Phase 0 trial design A phase 0 trial design was selected, as it allows for a rapid evaluation of the drug distribution and target engagement within the CS with minimal patient exposure, which is an important consideration in NF2 as it is a rare disease with a small patient population. This design will help to determine whether ritonavir and lopinavir reach therapeutic concentrations in the CS tissue and if they engage the intended targets before proceeding to larger studies to determine efficacy. Both drugs have a well-established safety profile from their use in HIV treatment, so we can start at the therapeutic dose. Objectives The primary aim is to investigate the distribution and biological activity of the HIV protease inhibitors, ritonavir and lopinavir, in peripheral schwannomas of the skin in NF2 patients. The secondary aims of the trial are: To determine steady-state plasma and intra-tumorous concentrations of ritonavir and lopinavir. To determine steady-state plasma and intra-tumorous concentrations of ritonavir and lopinavir. To assess the efficacy of ritonavir and lopinavir in reducing tumour cell proliferation and provide valuable insights into their potential as systemic treatments for NF2-related tumours. To assess the efficacy of ritonavir and lopinavir in reducing tumour cell proliferation and provide valuable insights into their potential as systemic treatments for NF2-related tumours. To establish the peripheral biomarkers’ predictive treatment response, it will be evaluated by testing target inhibition in peripheral blood mononuclear cells (PBMC). To establish the peripheral biomarkers’ predictive treatment response, it will be evaluated by testing target inhibition in peripheral blood mononuclear cells (PBMC). To assess the toxicity experienced by participants receiving the medication for 30 days. To assess the toxicity experienced by participants receiving the medication for 30 days. Methods and analysis Patient and public involvement The trial protocol was co-designed with patient involvement throughout to ensure their aims and priorities were central to the design and the protocol was acceptable from the patient/participant perspective. Active involvement of patients was established from the outset, including their participation in drafting the trial protocol, consent form and participant information sheet (PIS) and ongoing representation on the trial steering group. Trial design and setting This is an open label, phase 0 trial conducted at two sites: Derriford Hospital, Plymouth, and Northern Care Alliance NHS Foundation Trust, Manchester. The trial plans to recruit a maximum of 16 participants. Initially eight participants will be recruited, with a further eight in the cohort expansion group at a de-escalated dose level. Eligibility criteria Patients will be considered eligible for recruitment according to the trial entry criteria (table 1). Table 1Eligibility criteriaInclusion criteriaExclusion criteriaWritten informed consentHypersensitivity to ritonavir or lopinavir or any of its excipients.Diagnosis of NF2-related schwannomatosis as defined using the 2022 criteria.31Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4.Meningioma as identified by imagingCardiac arrhythmias requiring anti-arrhythmic (beta-blockers and digoxin are allowed). If a participant is being treated with digoxin, the monitoring recommendations of section 4.5 of the Kaletra SmPC must be followed during the trial.Over 18 years of ageSymptomatic coronary artery disease or ischemia.Peripheral schwannomas under the skin amenable to biopsyMyocardial infarction within the last 6 months; congestive cardiac failure > New York Heart Association Class II.Karnofsky performance status >60%Active clinically serious bacterial or fungal infections.Adequate bone marrow function within 28 days prior to the baseline visitKnown diagnosis of HIV infection or chronic hepatitis B or C.Adequate hepatic function within 28 days prior to the baseline visitPrior treatment with Norvir/Kaletra.Prothrombin or international normalised ratio and prothrombin time (PTT) <1.5× upper limit of normal (ULN)Pregnant or breastfeeding.Able to swallow tabletsPatients with uncontrolled hypertension.Patients with the potential for pregnancy or impregnating their partner must agree to use acceptable methods of birth control to avoid conception.Serious uncontrolled concomitant medical or psychiatric illness.Women of childbearing potential with a negative serum pregnancy test at screening and a negative urine pregnancy test at the baseline visit.Grade 3 or higher impairment of GI function or GI disease that may significantly alter the absorption of the trial drug.History of acute pancreatitis within 1 year of trial entry or medical history of chronic pancreatitis.History of another primary malignancy that is currently clinically significant or currently requires active intervention.Any other clinically significant medical or surgical condition that, according to the chief investigator/principal investigator’s discretion, should preclude participation.History of a significant congenital or acquired bleeding disorder.Patients taking warfarin or cytotoxic drugs.CYP3A4, cytochrome P450 3A4; GI, gastrointestinal; NF2, neurofibromatosis type 2; SmPC, summary of product characteristics. Eligibility criteria CYP3A4, cytochrome P450 3A4; GI, gastrointestinal; NF2, neurofibromatosis type 2; SmPC, summary of product characteristics. Intervention Name and description of investigational medicinal products (IMPs) Norvir (AbbVie): tablets containing 100 mg of ritonavir. Norvir (AbbVie): tablets containing 100 mg of ritonavir. Kaletra (AbbVie): tablets consisting of 100 mg of lopinavir and 25 mg of ritonavir. Kaletra (AbbVie): tablets consisting of 100 mg of lopinavir and 25 mg of ritonavir. Both Norvir and Kaletra have MAs in the UK for the treatment of HIV-1, and in this trial both drugs will be used outside of their MA and will be re-labelled for the trial. Dosing schedules Initial dosing The first five participants to be recruited will take 1 tablet of Kaletra and 2 tablets of Norvir by mouth, at approximately the same time each day, every 12 hours from day 1, following completion of the baseline procedures. They will continue the same dose for 30 days, with the last dose being taken in the morning of day 30 prior to the visit to the research clinic. The total daily dose will be 200 mg of lopinavir and 450 mg of ritonavir. Drug dosage for the trial was calculated based on IC50 values from in vitro data in patient-derived primary tumour cells.15 Cohort expansion The cohort of five will then be expanded to eight participants if exactly one participant demonstrates a pharmacodynamic (PD) response, which is significant at the 0.05 level. This methodology will be replicated at one de-escalated dose (Norvir reduced to 1 × 100 mg tablet two times daily, giving a total daily dose of 200 mg of lopinavir and 250 mg of ritonavir) if a significant PD response is observed in at least 2 of the initial five or the cohort expansion of eight participants. Thus, a maximum of 8+8 = 16 participants. See figure 1 for dosing schedule. Dosing schedule. PD, pharmacodynamics. Missed doses From day 1 (baseline visit) to day 14 (±1 day – visit 4), if the morning or evening dose is delayed for more than 6 hours, the patient should skip this dose and resume dosing with the next dose. For data analysis purposes, up to three doses may be missed before day 15. Between days 15 and 30, no missed doses are acceptable. If this occurs and site staff are made aware, participants should be informed that they can stop taking the medication to avoid adverse events (AEs). If an overdose with trial medications is reported, the participant will be advised to seek emergency medical attention. All incidences of drug overdose will be reported as a serious adverse event (SAE). Outcomes The primary outcome measure is PD response: a statistically significant decrease in biomarker activity in CS biopsies after 30 days of treatment. This is assessed by western blotting to measure: ERK1/2, Cyclin D1, Cleaved Caspase 3 and Cleaved Poly(ADP-ribose) polymerase 1 (PARP1). Extended biomarkers: phospho focal adhesion kinase (FAK)/FAK, p53, phospho S6, cJun, phospho protein kinase B (AKT)/AKT, multi-drug resistance protein 1 (MDR-1). The dose level is declared effective if at least 2 of the initial five or second stage 8 (5+3) participants demonstrate a PD response, which is significant at the 0.05 level. If a response is not observed in at least 2 of the eight participants, it will be considered that the primary endpoint is not reached, so the power calculations propose a maximum of eight more participants.21 Secondary outcomes include: To determine steady-state plasma and intra-tumorous (CS) concentrations of ritonavir and lopinavir (Kaletra plus Norvir) after 30 days of oral dosing—measured by pharmacokinetic analysis of blood and tissue samples (μg/kg). To determine steady-state plasma and intra-tumorous (CS) concentrations of ritonavir and lopinavir (Kaletra plus Norvir) after 30 days of oral dosing—measured by pharmacokinetic analysis of blood and tissue samples (μg/kg). Assessment of biomarkers for treatment response in patients by testing target inhibition in PBMC—measured by western blotting for: ERK1/2, phospho ERK1/2, cyclin D1 and cleaved caspase 3. Assessment of biomarkers for treatment response in patients by testing target inhibition in PBMC—measured by western blotting for: ERK1/2, phospho ERK1/2, cyclin D1 and cleaved caspase 3. Determine minimal biological effective dose—measured by PD response in ≥2 of 5 or 8 patients (significance at 0.05 level). Determine minimal biological effective dose—measured by PD response in ≥2 of 5 or 8 patients (significance at 0.05 level). To assess toxicity of ritonavir and lopinavir (Kaletra plus ritonavir) in patients treated at this dose schedule for meningioma or schwannoma—measured by collection and analysis of safety data in meningioma or schwannoma patients. To assess toxicity of ritonavir and lopinavir (Kaletra plus ritonavir) in patients treated at this dose schedule for meningioma or schwannoma—measured by collection and analysis of safety data in meningioma or schwannoma patients. Data collection methods Table 2 shows a summary of the trial data collection by time point. Assessments involve data collection and physical assessments. Appropriately trained staff at the study sites will carry out the physical assessments, collect the data and enter the data either directly onto the study database or on paper case report forms (CRFs) to be entered into the database retrospectively. Following target inhibition and pharmacokinetic analysis, results will be entered directly onto the study database. Table 2Tabulated summary of the trial data collection by time pointObjectivesOutcome measuresTimepoint(s) of evaluation of this outcome measure (if applicable)Primary objectiveTo determine the biological effect of trial medication (Kaletra plus Norvir) at steady-state concentration by investigation of molecular target inhibition in peripheral subcutaneous schwannoma (CS) tissues after oral drug administration for 30 days in comparison to baseline (first biopsy).Target inhibition will be analysed in the tumour before and after drug treatment via Wes, an automated capillary-based immunoassay quantitative system, to determine the levels of:Phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2 (proliferation marker);Cyclin D1 (cell cycle progression marker);Cleaved (active) caspase 3 (apoptosis marker);Cleaved PARP1 (apoptosis) as main targets.This will be complemented by an extended biomarker investigation looking for the effect of ritonavir and lopinavir on:Phospho FAK/FAK, p53.Phospho S6 ribosomal protein/s6;cJun, phospho AKT/AKT;P-glycoprotein (MDR-1).Days 0 and 30Secondary objectivesTo determine steady-state plasma and intra-tumorous (CS) concentrations of ritonavir and lopinavir (Kaletra plus Norvir) after 30 days of oral dosing.Drug concentration (μg/kg) from PK blood and tissue samples.Day 30Assessment of biomarkers for treatment response in participants by testing target inhibition in PBMC after 30 days of dosing.Western blotting will be performed for detection of:Phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2 (proliferation marker);Cyclin D1 (cell cycle progression marker);Cleaved (active) caspase 3 (apoptosis marker).Day 30Determine the minimal biological effective dose.The dose level is declared effective if at least 2 of the initial five or second stage 8 (5+3) participants demonstrate a PD response that is significant at the 0.05 level.Days 0 and 30To assess toxicity of ritonavir and lopinavir (Kaletra plus Norvir) in participants treated at this dose schedule for 30 days for meningioma or schwannoma.AEs, SAEs, ARs, SARs and SUSARs.Days 0–60AE, adverse event; AR, adverse reaction; PBMC, peripheral blood mononuclear cell; PD, pharmacodynamic; SAE, serious adverse event; SAR, serious adverse reaction; SUSAR, suspected unexpected serious adverse reaction. Tabulated summary of the trial data collection by time point Phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2 (proliferation marker); Phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2 (proliferation marker); Cyclin D1 (cell cycle progression marker); Cyclin D1 (cell cycle progression marker); Cleaved (active) caspase 3 (apoptosis marker); Cleaved (active) caspase 3 (apoptosis marker); Cleaved PARP1 (apoptosis) as main targets. Cleaved PARP1 (apoptosis) as main targets. This will be complemented by an extended biomarker investigation looking for the effect of ritonavir and lopinavir on:Phospho FAK/FAK, p53.Phospho S6 ribosomal protein/s6;cJun, phospho AKT/AKT;P-glycoprotein (MDR-1). This will be complemented by an extended biomarker investigation looking for the effect of ritonavir and lopinavir on: Phospho FAK/FAK, p53. Phospho FAK/FAK, p53. Phospho S6 ribosomal protein/s6; Phospho S6 ribosomal protein/s6; cJun, phospho AKT/AKT; cJun, phospho AKT/AKT; P-glycoprotein (MDR-1). P-glycoprotein (MDR-1). Phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2 (proliferation marker); Phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2 (proliferation marker); Cyclin D1 (cell cycle progression marker); Cyclin D1 (cell cycle progression marker); Cleaved (active) caspase 3 (apoptosis marker). Cleaved (active) caspase 3 (apoptosis marker). AE, adverse event; AR, adverse reaction; PBMC, peripheral blood mononuclear cell; PD, pharmacodynamic; SAE, serious adverse event; SAR, serious adverse reaction; SUSAR, suspected unexpected serious adverse reaction. Harms Adverse drug reactions A comprehensive list of previously reported side effects, a tabulated list of expected adverse reactions, contraindications and warnings and precautions for the use of ritonavir and lopinavir are listed in the current version of the summary of product characteristics (SmPC). These lists will be used to perform expectedness assessments where required. Withdrawal from trial If participants withdraw from the trial or stop taking trial medication at any time during the dosing period, where possible, an explanation for the decision will be elicited from the participant and recorded in the CRF. Any participant who becomes pregnant while participating before day 30 will discontinue trial medication and be withdrawn from the trial. If the participant has already stopped taking the trial medication, follow-up should continue as per the trial schedule. Adverse events All SAEs will be collected from the signing of the ICF until the end of the trial follow-up visit (day 60). The sponsor will be notified promptly of any SAEs. Suspected unexpected serious adverse reactions (SUSARs) will be reported to the MHRA as per the legal requirements (fatal or life-threatening SUSARs within 7 days and others within 15 days). All deaths will be reported to the sponsor irrespective of whether the death is related to disease progression, the IMP, or an unrelated event. Deaths should be reported as soon as a research site is aware to the trials unit, who will then forward to the sponsor within 24 hours. Participant timeline The participant flow is summarised in the trial flow diagram (figure 2). Trial flow chart. Screening and consent (visit 1) Consent to participate in the trial and screening assessments will take place at the screening visit. The participant’s general practitioner (GP) will be informed by letter. Each participant will be given a trial contact card stating that the holder is participating in a clinical trial and providing a 24-hour contact telephone number to contact the site research team. The participant will be assigned a unique trial number. Participants will be identified in all trial-related documentation by their trial number and initials. Baseline visit (visit 2, day 0) Participants will have an appointment at the research site within 28 days of the screening visit. Willingness to continue with the trial will be verbally confirmed. Following baseline assessments, the first administration of trial medication will be taken. The participant will be given sufficient trial medication for dosing at home until the morning of visit 5. Verbal instructions on how to take the drug will be given by the research team. Participants will be given instruction by the site research team on how to complete a trial diary card, which also provides 24-hour emergency contact details. Each time participants take trial medication, they should complete the trial diary card with the date and time. They will be asked to take the trial diary card and any unused medication and packaging with them each time they attend the research clinic. Days 2–6 Participants will continue to take trial medication two times daily at home and complete the trial diary card. Visit 3: Day 7 (±1 day) At day 7, participants will attend the research clinic for safety assessments. Days 8–13 Participants will continue to take trial medication two times daily at home and complete the trial diary card. Visit 4: Day 14 (±1 day) In the morning of day 14, participants will take their dose of trial medication at home. A member of the research team will contact the participant via telephone. Alternative/supplementary arrangements will be made for any participants with hearing loss. Visit 5: Day 30 On day 30, participants will take their last dose of trial medication at home prior to attending the research clinic for trial assessments. A second trial diary card will be provided by the site research team to record AEs and any concomitant medications taken in the period from the end of dosing to the end of the trial follow-up visit. Participants will be asked to return the diary card and any unused medication and packaging to the site research team at visit 6. Visit 6: End of trial follow-up day 60 (±2 days) The participant will attend the research site for the end-of-trial follow-up visit. If the participant has had a routine MRI scan during their participation in the trial, these data (including images) will also be collected. Individual participants will complete the trial after the end of the trial’s follow-up visit. The trial will end on the date that the last participant attends their last visit. The duration of the trial for each participant will be a maximum of 28 days from the screening (visit 1) visit to the end of trial follow-up visit at day 60 (visit 6). End of trial The end of the trial is defined as the end of the trial follow-up visit (visit 6 day 60 ± 2 days) for the last participant recruited. Description of clinical assessments and procedures Table 3 shows the assessment or procedure described below that will be undertaken at each visit. Medical history Table 3Assessments or procedures undertaken at each trial visitProcedure/data collectedVisit 1:screening and consentVisit 2:baseline(Day 0)Visit 3:day 7 (±1 day)Visit 4:day 14 (±1 day)Days 8–13Visit 5:day 30Visit 6:end of trial Follow-up: Day 60 (±2 days)Informed consentXDemographics (age, sex, ethnicity, postcode)XWeight, height, and BMIXMedical history (check of HIV and hepatitis B and C status).XPhysical and neurological examinationXXXBlood pressureXXXXXBlood sampleXXXCS biopsy for target inhibition analysisXXConcomitant medicationsXXX XXSerum pregnancy test (women of childbearing potential)XXMcGill Pain Questionnaire to measure tumour painXXXVAS to measure tumour painXXXAEsXXXXXTrial diary card 1XXxxTrial diary card 2XXInspection of screening biopsy siteXXXXCheck of compliance with the trial dosing scheduleXXXCollection of MRI results, if applicableXAE, adverse event; BMI, body mass index; VAS, visual analogue scale. Assessments or procedures undertaken at each trial visit AE, adverse event; BMI, body mass index; VAS, visual analogue scale. A full medical history will be taken from the patient and their available medical records. Demographics (age, sex, ethnicity and postcode), weight, height and body mass index (BMI) will be recorded. Physical examination This will include examination of the head, eyes, throat lymph nodes, skin, respiratory system, cardiovascular system, abdomen, and musculoskeletal system. Neurological examination This will include a cranial nerve assessment, motor examination, sensory examination, reflexes and coordination assessment. Pregnancy testing A serum pregnancy test will be performed on women of childbearing potential at screening. At baseline, women of childbearing potential will be asked to provide a sample of urine for pregnancy testing. Blood pressure Blood pressure will be recorded using a sphygmomanometer. Pain assessments The McGill Pain Questionnaire will be completed by participants to analyse if tumour pain occurs after treatment. Data collected will be the Pain Rating Index (PRI).22 The McGill Pain Questionnaire will be completed by participants to analyse if tumour pain occurs after treatment. Data collected will be the Pain Rating Index (PRI).22 Visual Analogue Scale (VAS, pain): A VAS scale of current pain will be completed by participants.23 Visual Analogue Scale (VAS, pain): A VAS scale of current pain will be completed by participants.23 Blood sampling Laboratory Safety Testing Approximately 8 mL whole blood will be collected and will be analysed as per standard local clinical laboratory procedures for: Haematology: Haemoglobin, platelets, white cell count and differentials. Haematology: Haemoglobin, platelets, white cell count and differentials. Clinical chemistry: Urea, sodium, potassium, magnesium, calcium, phosphorus, creatinine, amylase and lipase Clinical chemistry: Urea, sodium, potassium, magnesium, calcium, phosphorus, creatinine, amylase and lipase Liver function tests: Aspartate transferase, alanine transaminase, total bilirubin and albumin. Liver function tests: Aspartate transferase, alanine transaminase, total bilirubin and albumin. Coagulation: Fibrinogen, prothrombin time and partial thromboplastin time. Coagulation: Fibrinogen, prothrombin time and partial thromboplastin time. Serology for HIV, Hepatitis B & C status Serology for HIV, Hepatitis B & C status The PI will check for clinically significant out-of-range results and report them as AEs where appropriate. Blood analysis for predictive biomarkers for target engagement and response To identify predictive biomarkers for treatment response, PBMCs will be isolated from whole blood samples collected at both screening (visit 1) and day 30 (visit 5). These PBMCs will then be analysed for proliferation (phosphorylated ERK1/2), cell cycle progression (cyclin D1) and apoptosis (cleaved caspase 3). The findings will be correlated with target inhibition data obtained from tissue analysis. PBMC isolation will be performed promptly using the EZPREP PBMC Isolation Kit (ZenBio, Inc., USA).24 Following isolation, western blot analysis will be conducted to detect both phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2, cyclin D1 and cleaved (active) caspase 3. Tissue sampling A doctor will identify the most clinically appropriate CS or two CSs accessible for biopsy (up to two biopsies, >1 cm3). Samples will be surgically excised by an appropriately qualified doctor employing an aseptic technique. If there are problems with the first CS sample, a further biopsy may be taken; if the PI considers that a second tumour biopsy sample is appropriate, he participant agrees. Only one additional sampling will be permitted. If the participant declines to provide a second sample at screening, this will be regarded as a screening failure. If the participant declines to provide a second sample at day 30, they will be withdrawn from the trial. Participants will be given advice on appropriate care of their wound and where to seek help if required. A member of the site research team will inspect the biopsy site(s) each time a participant attends the research clinic. Observations will be recorded, and any concerns will be reported to the PI and reported as AEs if appropriate. Tissue processing Within 30 min of collection, the pseudonymised CS tissue sample(s) will be sent (fresh and NOT in formalin) to the histopathology laboratory, weighed and divided into three. One sample is kept at the local histopathology laboratory for histopathology diagnosis. The two additional samples will be frozen and kept at –80°C or kept on dry ice before being transferred to the Derriford Research Facility, University of Plymouth (DRF), for analysis of tissue concentration of ritonavir and lopinavir and target inhibition analysis. A laboratory manual for collecting, preparing, packing and dispatching samples will be kept in the Investigator Site File (ISF). Tissue analysis for diagnosis, target engagement and response Confirmation of schwannoma will take place immediately in the local histopathology lab to ensure the participant is eligible for inclusion (visit 1) and that a repeat biopsy is not indicated (visit 1 and day 30). Target inhibition in CS tissue samples All samples for target inhibition will be labelled with the participant number and a unique anonymous code to conceal whether the sample is pre- or post-administration of trial medication. Analysis will be undertaken on batches of samples from five participants at a time. Target inhibition will be analysed by investigating the therapeutic targets, total and phosphorylated ERK1/2, cyclin D1 and cleaved caspase 3, using western blot. The effect of ritonavir and lopinavir on proliferation (Ki67) and apoptosis (cleaved caspase 3) will be investigated by immunohistochemistry (IHC).16 The expression of pro-inflammatory cytokines, IL-6 and TNFα25 and the number of CD8+ and CD3+T cells and the number of M2 CD163+ polarised macrophages will be evaluated using IHC and western blotting.26 27 All samples must be investigated simultaneously using the same western blot gel. Pharmacokinetic (PK) analysis PK analysis on blood plasma and tissue will be conducted by Pharmidex Pharmaceutical Services Ltd., UK. Anonymised samples of tumour tissue (minimum wet weight of 200 mg) and blood plasma will be stored in a freezer set at or below −80°C at DRF and couriered to the company in batches on dry ice. Sample size The sample size calculation is based on the tissue biomarker response. To target a true 40% PD response rate, a two-stage design will be used.28 This methodology will be replicated at one deescalated dose if a significant PD response is observed in at least 2 of the initial five or in the cohort expansion of eight participants. Thus, a maximum of 8 + 8 = 16 participants. Recruitment Patients with NF2-related schwannomatosis and CS from the two sites will be identified, screened and recruited into the trial via three routes: Investigators’ clinical patient database, responders to information on relevant websites and social media and patient identification centres (PICs). Data management Participant screening and outcome data will be entered into REDCap, a web-based data capture system, by authorised personnel from participating NHS sites. Access to REDCap is regulated using usernames, encrypted passwords and two-factor authentication. The system maintains an electronic audit trail and hosts in-built validation mechanisms to ensure data integrity and security, including validation checks at the point of data entry. To ensure data quality and completeness, the Peninsula Clinical Trials Unit (PenCTU) data team will regularly monitor the data using validated R scripts. Details of these monitoring and validation activities are outlined in the data management plan (DMP), available on request. The monitoring process includes post-entry validation checks, ensuring completeness of critical data items, surveillance of safety and withdrawal reports and audit trail monitoring. The data manager will provide ongoing reports to the Trial Management Group (TMG) regarding data quality and completeness throughout the trial. Statistical methods A detailed statistical analysis plan (SAP) will be drafted by the trial statisticians and approved by an independent statistician prior to database lock. The trial will be reported following the relevant Consolidated Standards of Reporting Trial (CONSORT) guidelines.29 Descriptive statistics of participants’ demographic and baseline characteristics will be presented using means (SD and SE of the mean (SEM)), median (IQR) and range, where appropriate and count (percentage). Assessment of PD response The primary outcome is PD response and is assessed for protocol-compliant participants (who received the protocol-required drug exposure and required protocol processing). For each pair of biomarker measurements (baseline and 30 days), the ratio of the responses after/before will be computed. If there is more than one reading for any biomarker at any timepoint for any participant, the mean will be taken. The ratios will be placed on a log scale to stabilise variation and to achieve approximately symmetric distributions. A one-tailed test of the null hypotheses H0: log ratio=0 versus H1: log ratio<0 will be conducted for each patient using the assumed common standard deviation (of the ratios between patients). P values will be obtained from the t-distribution. The dose level is declared effective if at least two of the first stage five or second stage eight participants demonstrate a PD response, which is significant at the 0.05 level for at least one biomarker. Assessment of treatment response in participants by testing target inhibition in PBMC Target inhibition analysis using western blotting will be performed for the detection of phosphorylated (active) and total (phosphorylated and non-phosphorylated) ERK1/2 (proliferation marker), cyclin D1 (cell cycle progression marker) and cleaved (active) caspase 3 (apoptosis marker). The data will be summarised similarly to the primary outcome; however, it will not inform the decision on dose effectiveness. Assessment of PK response To determine steady-state plasma and intra-tumorous concentrations of trial medication after 30 days of oral dosing: The drug concentration in blood and tissue biopsies, measured using PK analysis, will be descriptively summarised at day 30. Safety and toxicity of trial medication will be assessed in the as-treated population (any participant receiving at least one dose of the trial drug). The total number and percentage of participants reporting an AE will be presented along with the number of events per participant, the type of event (MedDRA preferred term), severity grading and relatedness to treatment (causality). There will be no imputation used to estimate missing outcome data. Missing data will be summarised. Data monitoring committee As this is a phase 0, open-label (unblinded) clinical trial of an investigational medicinal product (CTIMP) with laboratory-based outcomes, there is no Data Monitoring Committee (DMC). A Trial Steering Committee (TSC) will oversee the conduct and safety of the trial and will include the CI (or his authorised delegate), an independent chair and independent member(s), the PenCTU trial manager, trial statisticians and a patient representative. Trial monitoring The trial will be conducted in compliance with the principles of Good Clinical Practice (GCP). PenCTU, in accordance with its Risk Assessment and Monitoring SOPs, will develop the trial monitoring based on the trial risk assessment with input from the TMG. A monitoring plan will be signed off by the CI and sponsor before implementation. This will detail the requirements for central and on-site monitoring (where visits will be hosted by the investigator site PI and relevant members of their team). PenCTU staff will undertake monitoring activities. Audits and inspections may be undertaken as appropriate to ensure compliance with the approved trial protocol, the applicable SOPs and the principles of GCP. Ethics and dissemination Research ethics approval The study was approved by an Ethics Committee (West of Scotland Research Ethics Service (23/WS/0178)), the MHRA and each of the participating NHS Trusts’ Research and Development departments. Dissemination policy Following the analysis of trial data, the results will be written up into a report by the CI. Appropriate acknowledgement will be given to all contributors to the trial. The trial results will be written up for publication in a peer-reviewed scientific journal and will be disseminated at conferences. Participants will be informed of the trial results by letter from the CI and PI(s). Protocol amendments Amendments will be notified to the HRA/REC, MHRA and communicated to the participating organisations (R&D office and local research team) and departments of participating sites to assess whether the amendment affects the NHS permission for that site. Some amendments may be considered to be non-substantial for the purposes of REC and will still be notified to NHS R&D. Amended documents will be allocated a new sequential version number. Once approved, this version will supersede any previous versions. A record of amendments will be maintained by PenCTU. Consent Consent to participate in the trial will take place at the screening visit. Potential participants will be provided with the PIS ahead of the screening visit to allow time to read the literature and consider their participation. Written informed consent will be obtained before any screening or other trial-related activity is undertaken. The consent procedure will be undertaken by the principal investigator (PI) or their authorised delegate. An original signed informed consent form (ICF) will be retained in the trial site file, a copy will be given to the patient, and a copy will be placed in the participant’s hospital notes. Participants have the right to refuse participation without explanation and can withdraw from the trial at any time without affecting their future care. If a participant consents but later declines treatment or is deemed unsuitable, this will be recorded, and no further data will be collected. It will be made clear to the participant that as this is a phase 0 trial, it is unlikely that they will benefit clinically from participation. Researchers must not coerce or unduly influence participants during the consent process. The PIS and ICF must be the most current versions approved, with version numbers and dates clearly printed. The PI retains overall responsibility for the informed consent of participants at their site and must ensure that any person delegated responsibility to participate in the informed consent process is duly authorised, trained and competent to do so according to the ethically approved protocol, principles of good clinical practice (GCP) and Declaration of Helsinki 1996. Confidentiality To ensure participant confidentiality, the dataset will undergo anonymisation before any data dissemination.30 No direct identifiers will be shared with the trial statisticians, and access to directly identifiable information within the data capture system will be restricted. The trial adheres to relevant data protection legislation, including compliance with the HRA’s General Data Protection Regulation. Data will be retained and accessible for 5 years post-trial completion. Trial registration ISRCTN10422213 https://doi.org/10.1186/ISRCTN10422213 Registration date: 22/02/2024 Protocol and statistical analysis plan Details about the protocol and SAP will be accessible via the study page on the ISRCTN register. Data sharing Access to the dataset will be granted to the Sponsor or Regulatory Authorities on request to permit trial-related monitoring, audits and inspections. Access will be overseen by the CTU data manager and trial manager. Access to the final dataset will be provided to the trial statisticians for analysis. Data generated from the trial (target inhibition and pharmacokinetic analysis) will be uploaded to the funder’s data sharing platform, ‘Synapse Neurofibromatosis Open Science Initiative (NF-OSI)’. Data will be embargoed during the award period and for 12 months thereafter. The data will then be made available to the broader research community as per the trial’s Data Sharing Plan.